Fax: (011) 33 5 56 33 33 83
Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?
Version of Record online: 21 APR 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 13, pages 3093–3101, 1 July 2010
How to Cite
Ragage, F., Debled, M., MacGrogan, G., Brouste, V., Desrousseaux, M., Soubeyran, I., Tunon de Lara, C., Mauriac, L. and de Mascarel, I. (2010), Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?. Cancer, 116: 3093–3101. doi: 10.1002/cncr.25137
- Issue online: 18 JUN 2010
- Version of Record online: 21 APR 2010
- Manuscript Accepted: 30 OCT 2009
- Manuscript Revised: 15 SEP 2009
- Manuscript Received: 13 JUL 2009
- breast cancer;
- lymphovascular invasion;
- lymph node positive
Lymphovascular invasion (LVI) is a widely recognized prognostic factor in lymph node-negative breast cancers. However, there are only limited and controversial data about its prognostic significance in lymph node-positive patients.
Among 931 patients operated on and monitored at the authors' institution for an invasive breast carcinoma between 1989 and 1992, all 374 lymph node-positive breast cancers entered the study (median follow-up, 126 months).
LVI was present in 46% of tumors and was associated with age ≤40 years (P = .02), high histological grade (P = .01), and negative estrogen receptor status (P = .032), but not with tumor size, number of involved lymph nodes, or HER-2/neu status. LVI was an independent prognostic factor for distant metastases (P = .002). Furthermore, in HER-2/neu–negative/hormone receptor-positive (n = 287) tumors, the number of independent prognostic factors (LVI, age, histological grade, number of involved lymph nodes, and tumor size) was associated with a 5-years metastasis-free survival ranging from 100% if no factors (n = 25) to 89% ± 2% if 1 or 2 factors (n = 186) and 67% ± 6 if 3, 4, or 5 factors (n = 76) were present (P < .001).
LVI is an independent prognostic factor in lymph node-positive breast cancer and merits further prospective investigations as a decision tool in the adjuvant chemotherapy setting. Cancer 2010. © 2010 American Cancer Society.